Dimos Karangelis

Prof. Dr. Dimos Karangelis

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in European Journal of Sport Science
Verified
Journal Article
Closed access
TKTheocharis Koufakis
Theocharis Koufakis
Spyridon KarrasSpyridon Karras
Spyridon Karras
OMOmar G. Mustafa
Omar G. Mustafa
Dimos KarangelisDimos Karangelis
Dimos Karangelis
PZPantelis Zebekakis
Pantelis Zebekakis
KKKalliopi Kotsa
Kalliopi Kotsa
People with diabetes, particularly those being insulin treated, have been for many years considered ineligible for diving, because of the high risk of adverse events. Blood glucose levels tend to decline during diving, probably because of changes in insulin requirements and resistance, due to increased physical activity and effects of hyperbaric environment on glucose tolerance. Strict adherence to safety protocols, in conjunction with optimal physical status, lack of diabetic complications (especially impaired awareness of hypoglycaemia) and satisfactory baseline glycaemic control, seem to minimise the risk of complications during diving. The integration of modern technology into diabetes management, providing potential for underwater continuous glucose monitoring, can be useful in optimising metabolic control before, during and after diving. Despite the significant progress been made on safety issues, there is still a need to implement the relevant recommendations into divers’ everyday practice. Existing evidence is mainly derived from small studies and there is a wide heterogeneity in terms of study designs and explored outcomes, rendering the extraction of definitive conclusions challenging. The aim of this review is to present and critically evaluate available evidence, use of technology, and gaps in existing knowledge that deserve further evaluation by future studies.

11 January 2022 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Open access
PDF file
IMImthiaz Manoly
Imthiaz Manoly
MUMohsin Uzzaman
Mohsin Uzzaman
Dimos KarangelisDimos Karangelis
Dimos Karangelis
MKManoj Kuduvalli
Manoj Kuduvalli
Efstratios GeorgakarakosEfstratios Georgakarakos
Efstratios Georgakarakos
Abdul NasirAbdul Nasir
Abdul Nasir
Deep hypothermic circulatory arrest (DHCA) in aortic surgery is associated with morbidity and mortality despite evolving strategies. With the advent of antegrade cerebral perfusion (ACP), moderate hypothermic circulatory arrest (MHCA) was reported to have better outcomes than DHCA. There is no standardised guideline or consensus regarding the hypothermic strategies to be employed in open aortic surgery. Meta-analysis was performed comparing DHCA with MHCA + ACP in patients having aortic surgery. A systematic review of the literature was undertaken. Any studies with DHCA versus MHCA + ACP in aortic surgeries were selected according to specific inclusion criteria and analysed to generate summative data. Statistical analysis was performed using STATS Direct. The primary outcomes were hospital mortality and post-operative stroke. Secondary outcomes were cardiopulmonary bypass time (CPB), post-operative blood transfusion, length of ICU stay, respiratory complications, renal failure and length of hospital stay. Subgroup analysis of primary outcomes for Arch surgery alone was also performed. Fifteen studies were included with a total of 5869 patients. There was significantly reduced mortality (Pooled OR = +0.64, 95% CI = +0.49 to +0.83; p = 0.0006) and stroke rate (Pooled OR = +0.62, 95% CI = +0.49 to +0.79; p < 0.001) in the MHCA group. MHCA was associated significantly with shorter CPB times, shorter duration in ICU, less pulmonary complications, and reduced rates of sepsis. There was no statistical difference between the two groups in terms of circulatory arrest times, X-Clamp times, total operation duration, transfusion requirements, renal failure and post-op hospital stay. MHCA + ACP are associated with significantly better post-operative outcomes compared with DHCA for both mortality and stroke and majority of the secondary outcomes.

17 August 2010 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
Dimos KarangelisDimos Karangelis
Dimos Karangelis
GTGeorgios I. Tagarakis
Georgios I. Tagarakis
MDMarios Daskalopoulos
Marios Daskalopoulos
GSGeorgios Skoumis
Georgios Skoumis
NDNicholaos Desimonas
Nicholaos Desimonas
NTNikolaos B Tsilimingas
Nikolaos B Tsilimingas
The aim of the present study was to evaluate the efficacy of autologous blood pleurodesis in the management of persistent air leak in spontaneous pneumothorax. A number of 15 patients (10 male and 5 female) were included in this prospective study between March 2005 and December 2009. The duration of the air leak exceeded 7 days in all patients. The application of blood pleurodesis was used as the last preoperative conservative method of treatment in 12 patients. One patient refused surgery and two were ineligible for operation due to their comorbidities. A blood sample of 50 ml was obtained from the patient's femoral vein and immediately introduced into the chest tube. A success rate of 27% was observed having the air leak sealed in 4 patients in less than 24 hours. Despite our disappointingly poor outcome, the authors believe that the procedure's safety, convenience and low cost establish it as a worth trying method of conservative treatment for patients with the aforementioned pathology for whom no other alternative than surgery would be a choice.

26 August 2020 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
Dimos KarangelisDimos Karangelis
Dimos Karangelis
SLSpiros Loggos
Spiros Loggos
ATAphrodite Tzifa
Aphrodite Tzifa
FMFotios A. Mitropoulos
Fotios A. Mitropoulos
Purpose of review Aberrant subclavian artery (ASCA) represents one of the most common congenital vascular anomalies of the aortic arch. The majority of ASCAs are associated with an aneurysm which occurs at their origin from the descending thoracic aorta, namely, the Kommerell's diverticulum. In this review, we discuss recent data with regards to indications of treatment and surgical management of these anatomical variants. Recent findings Various surgical methods have been described for the repair of ASCA and Kommerell's diverticulum. Traditionally, treatment included open surgery; however, recent studies describe a shift of conventional treatment to more hybrid or endovascular approaches. The heterogeneity in the anatomy and presentation of these clinical entities as well as patient-related factors have prevented conduction of randomized trials for the best available modality of treatment. This dearth of literature is well depicted in the current guidelines. Summary The optimal surgical procedure has to be tailored to every patient according to the presentation, individual anatomy, and patient's risk profile. Conventional surgery for ASCA and Kommerell's diverticulum has acceptable mortality and complication rates, whereas hybrid repairs report encouraging results. Further studies are required to provide sufficient evidence which will formulate a clear frame of treatment indications and optimal surgical methods, as well as evaluate long-term results following hybrid repair.

1 June 2018 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
Dimos KarangelisDimos Karangelis
Dimos Karangelis
AMAmine Mazine
Amine Mazine
SNSreekanth Narsupalli
Sreekanth Narsupalli
SMShamarli Mendis
Shamarli Mendis
GVGruschen Veldtman
Gruschen Veldtman
NNNicolas Nikolaidis
Nicolas Nikolaidis

Verified
Journal Article
Open access
PDF file
Theodora Maria StougiannouTheodora Maria Stougiannou
Theodora Maria Stougiannou
KCKonstantinos C. Christodoulou
Konstantinos C. Christodoulou
IDIoannis Dimarakis
Ioannis Dimarakis
DMDimitrios Mikroulis
Dimitrios Mikroulis
Dimos KarangelisDimos Karangelis
Dimos Karangelis
Despite improvements in contemporary medical and surgical therapies, cardiovascular disease (CVD) remains a significant cause of worldwide morbidity and mortality; more specifically, ischemic heart disease (IHD) may affect individuals as young as 20 years old. Typically managed with guideline-directed medical therapy, interventional or surgical methods, the incurred cardiomyocyte loss is not always completely reversible; however, recent research into various stem cell (SC) populations has highlighted their potential for the treatment and perhaps regeneration of injured cardiac tissue, either directly through cellular replacement or indirectly through local paracrine effects. Different stem cell (SC) types have been employed in studies of infarcted myocardium, both in animal models of myocardial infarction (MI) as well as in clinical studies of MI patients, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), Muse cells, multipotent stem cells such as bone marrow-derived cells, mesenchymal stem cells (MSCs) and cardiac stem and progenitor cells (CSC/CPCs). These have been delivered as is, in the form of cell therapies, or have been used to generate tissue-engineered (TE) constructs with variable results. In this text, we sought to perform a narrative review of experimental and clinical studies employing various stem cells (SC) for the treatment of infarcted myocardium within the last two decades, with an emphasis on therapies administered through thoracic incision or through percutaneous coronary interventions (PCI), to elucidate possible mechanisms of action and therapeutic effects of such cell therapies when employed in a surgical or interventional manner.